Center for Health Behavior Research
| Grants | home |
|
Center for Health Behavior Research |
Grants Awarded
1996 -2000
1997 - SANO Corporation, "The Evaluation of the Efficacy and Safety of a Transdermal Delivery System of Nicotine/Mecamylamine in Cigarette Smokers."
1997 - DynaGen, Inc., "The Determination of the Sensitivity of the NicCheck I Test in Identifying the Use of Smokeless Tobacco."
1997 - SANO Corporation, "The Evaluation of Continuous Abstinence at Three, Six, and Twelve Months After the Quit Date in Nicotine/Mecamylamine Transdermal Studies."
1997 - SANO Corporation, "The Evaluation of the Efficacy and Safety of a Transdermal Delivery System of Nicotine/Mecamylamine in Cigarette Smokers with a History of Hypertension who are Maintained on Antihypertensive Pharmacotherapy."
1997 - SANO Corporation, "The Evaluation of the Safety of a Transdermal Delivery System of Nicotine/Mecamylamine in Cigarette Smokers in Patients with Gastrointestinal Disorders."
1998 - Glaxo Wellcome, "A Multi-Center Evaluation of the Effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus Placebo in a Population of Smokers with COPD."
1998 - Glaxo Wellcome, "A Double-Blind Placebo-Controlled Clinical & Safety Evaluation of Zyban™ for Smokeless Tobacco Cessation."
1998 - Glaxo Wellcome, "A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of 1555U88 (2.5mg/day, 5mg/day, 10mg/day, 15mg/day) and Zyban™ (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation."
1998 - SmithKline Beecham Consumer Healthcare, "A Randomized, Double-Blind, Parallel Group Study to Measure the Efficacy & Safety of Nicotine Gum (2mg & 4mg) for Smoking Cessation by Gradual Reduction."
1999 - Knoll Pharmaceutical Company, "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy & Safety of Meridia (sibutramine hydrochloride) Plus Adjunctive Nicotine Therapy (Habitrol Patch) as an Aid for Smoking Cessation in Patients who Smoke Cigarettes."
1999 - Bristol-Myers Squibb, "A Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Buspirone as an Aid to Smoking Cessation."
1999 - Pharmacia & Upjohn, "A Double-Blind, Randomized, Placebo-Controlled Multi-Center Trial of a Nicotine Inhaler in Smoking Reduction: A 15-month Trial."
1999 - Synthelabo Research Inc., "Comparison of the Efficacy & Safety of 3 Oral Doses of Befloxatone 2.5 mg/day, 5 mg/day & 10 mg/day Versus Placebo as an Aid to Smoking Cessation in Smokers: A Randomized, Double-Blind, 6-Month Multi-Center Phase II Trial 10-Week Active Treatment - 3.5-Month Follow-Up."
1999 - Glaxo Wellcome, "A Multi-Center, Randomized, Parallel, Placebo-Controlled, One-Year Study of the Efficacy and Safety of Zyban™ (Bupropion Hydrochloride Sustained Release Tablets) versus Placebo as Aids to Smoking Cessation Treatment in Adult Cigarette Smokers Previously Treated with Bupropion."
1999 - Glaxo Wellcome, "A Multi-Center, Double-Blind. Placebo-Controlled Comparison of the Safety & Efficacy & Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release (SR) & Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression."
2000 - Eli Lilly Corporation, "Open-Label Combination of Olanzapine plus Fluoxetine in Major Depressive Disorder."
2000 - Pfizer, Inc., "A Seven-Week, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Safety and Efficacy of Three Doses of CP-526,555 (0.3 mg QD, 1 mg QD, and 1 mg BID) in Comparison with Zyban™ SR in Smoking Cessation."
2000 - Sanofi-Synthelabo Research, "A Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of SR141716 as an Aid to Smoking Cessation."
2000 - Parke-Davis Pharmaceuticals America, Inc., "A 6-Week, Double-Blind, Randomized, Multi-Center, Flexible-Dose, Placebo-Controlled Study of Pagoclone in Patients With Generalized Anxiety Disorder."
 |
|
|